BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1645622)

  • 1. Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.
    Niederle N; Ostermann J; Achterrath W; Lenaz L; Schmidt CG
    Cancer Chemother Pharmacol; 1991; 28(1):59-62. PubMed ID: 1645622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation.
    Ettinger DS; Bitran JD; Comis RL; Langer CJ; Harwood KV; Harris CL; Keller JH; Losada M
    Am J Clin Oncol; 1991 Apr; 14(2):127-32. PubMed ID: 1851388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
    Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
    J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer.
    O'Neill P; Clark PI; Smith D; Marshall E; Hannigan K; Ross G
    Oncology; 2001; 61 Suppl 1():25-9. PubMed ID: 11598411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.
    Chatelut E; Chevreau C; Blancy E; Lequellec A; Canal P; Roche H; Houin G; Bugat R
    Cancer Chemother Pharmacol; 1990; 26(5):365-8. PubMed ID: 2170043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer.
    Fukuoka M; Masuda N; Negoro S; Takada M; Kudoh S; Kusunoki Y; Matsui K; Takifuji N; Tachikawa A; Kawahara M
    Cancer; 1991 Jul; 68(2):284-8. PubMed ID: 2070326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer.
    Atagi S; Furuse K; Kawahara M; Kodama N; Ogawara M; Kubota K; Matsui K; Kusunoki Y; Masuda N; Takada M; Negoro S; Fukuoka M
    Jpn J Clin Oncol; 1996 Oct; 26(5):316-21. PubMed ID: 8895671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.
    Johnson DH; DeVore R; Greco FA; Walls J; Thomas M; Hande KR; Hainsworth JD
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):50-6. PubMed ID: 1329223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum/oral etoposide therapy in non-small cell lung cancer.
    Furuse K
    Oncology; 1992; 49 Suppl 1():63-9; discussion 70. PubMed ID: 1323814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
    Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
    Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer.
    Masuda N; Fukuoka M; Matsui K; Negoro S; Takada M; Sakai N; Ryu S; Takifuji N; Ito K; Kudoh S
    Cancer; 1990 Jun; 65(12):2635-40. PubMed ID: 1692757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.